title: Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
abstract: BACKGROUND
  Endoglin (ENG) is a 180-kilodalton transmembrane glycoprotein that functions as a component of the transforming growth factor-β receptor complex. Recently, ENG promoter hypermethylation was reported in several human cancers.
  
  
  METHODS
  The authors examined ENG promoter hypermethylation using real-time, quantitative, methylation-specific polymerase chain reaction in 260 human esophageal tissues.
  
  
  RESULTS
  ENG hypermethylation demonstrated highly discriminative receiver operating characteristic curve profiles, clearly distinguishing esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) from normal esophagus (P<.01). It is interesting to note that ENG normalized methylation values were significantly higher in ESCC compared with normal tissue (P<.01) or EAC (P<.01). The ENG hypermethylation frequency was 46.2% in ESCC and 11.9% in normal esophageal tissue, but increased early and sequentially during EAC-associated neoplastic progression to 13.3% in Barrett metaplasia (BE), 25% in dysplastic BE, and 26.9% in frank EAC. ENG hypermethylation was significantly higher in normal esophageal tissue from patients with ESCC (mean, 0.0186) than in normal tissue from patients with EAC (mean, 0.0117; P<.05). Treatment of KYSE220 ESCC cells with the demethylating agent 5-aza-2'-deoxycytidine was found to reverse ENG methylation and reactivate ENG mRNA expression.
  
  
  CONCLUSIONS
  Promoter hypermethylation of ENG appears to be a frequent, tissue-specific event in human ESCC and exhibits a field defect with promising biomarker potential for the early detection of ESCC. In addition, ENG hypermethylation occurs in a subset of human EAC, and early during BE-associated esophageal neoplastic progression.
authors.affiliation: Department of Pathology, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People's Republic of China; Shenzhen Key Laboratory of Micromolecule Innovative Drugs, Shenzhen, Guangdong, People's Republic of China; Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, People's Republic of China.
authors.forename: Zhe
authors.initials: Z
authors.lastname: Jin
authors.forename: Zhenfu
authors.initials: Z
authors.lastname: Zhao
authors.forename: Yulan
authors.initials: Y
authors.lastname: Cheng
authors.forename: Ming
authors.initials: M
authors.lastname: Dong
authors.forename: Xiaojing
authors.initials: X
authors.lastname: Zhang
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Xinmin
authors.initials: X
authors.lastname: Fan
authors.forename: Xianling
authors.initials: X
authors.lastname: Feng
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Mori
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Meltzer
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology; D000368:Aged; D015703:Antigens, CD / Q000235:genetics*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology; D016022:Case-Control Studies; D019175:DNA Methylation; D000077209:Decitabine; D000071063:Endoglin; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000473:pathology; D004947:Esophagus / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics; D012372:ROC Curve; D060888:Real-Time Polymerase Chain Reaction; D011956:Receptors, Cell Surface / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured
chemical_list: D015703:Antigens, CD; D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; C064206:ENG protein, human; D000071063:Endoglin; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D000077209:Decitabine; D001374:Azacitidine
keywords: biomarker; endoglin; esophageal adenocarcinoma; esophageal squamous cell carcinoma; hypermethylation
references.citation: Int J Cancer. 1999 May 17;81(4):568-72
references.pmid: 10225446
references.citation: Clin Cancer Res. 2008 Jun 15;14(12):3785-91
references.pmid: 18559597
references.citation: Semin Oncol. 2005 Oct;32(5):443-51
references.pmid: 16210084
references.citation: Cancer Res. 1999 Feb 15;59(4):856-61
references.pmid: 10029075
references.citation: Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7
references.pmid: 18199717
references.citation: Gastroenterology. 2006 Sep;131(3):797-808
references.pmid: 16952549
references.citation: Clin Cancer Res. 2007 Nov 1;13(21):6293-300
references.pmid: 17975140
references.citation: J Biol Chem. 1992 Sep 25;267(27):19027-30
references.pmid: 1326540
references.citation: Oncogene. 2007 Sep 20;26(43):6332-40
references.pmid: 17452981
references.citation: J Cell Physiol. 2001 Jul;188(1):1-7
references.pmid: 11382917
references.citation: Eur J Cancer. 2005 May;41(8):1223-36
references.pmid: 15911247
references.citation: Oncogene. 2011 Mar 3;30(9):1046-58
references.pmid: 21042283
references.citation: Prostate. 2002 Jun 1;51(4):268-75
references.pmid: 11987155
references.citation: Am J Hum Genet. 1997 Jul;61(1):68-79
references.pmid: 9245986
references.citation: Gut. 2007 Jan;56(1):13-9
references.pmid: 16785283
references.citation: Oncogene. 2005 Jun 9;24(25):4138-48
references.pmid: 15824739
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: J Biol Chem. 1990 May 25;265(15):8361-4
references.pmid: 1692830
references.citation: Cancer. 2001 Jun 15;91(12):2294-301
references.pmid: 11413518
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Front Med China. 2010 Dec;4(4):378-84
references.pmid: 21107750
references.citation: Oncogene. 2003 Apr 17;22(15):2352-60
references.pmid: 12700670
references.citation: Clin Cancer Res. 1995 Dec;1(12):1623-34
references.pmid: 9815965
references.citation: Hum Mol Genet. 1995 Oct;4(10):1983-5
references.pmid: 8595426
references.citation: Int J Cancer. 2008 Dec 15;123(12):2816-23
references.pmid: 18798555
references.citation: Diagn Mol Pathol. 2006 Mar;15(1):17-23
references.pmid: 16531764
references.citation: Cancer Res. 2003 Apr 1;63(7):1596-601
references.pmid: 12670910
references.citation: Anticancer Drugs. 2005 Mar;16(3):301-8
references.pmid: 15711182